Land: USA
Språk: engelsk
Kilde: NLM (National Library of Medicine)
FINGOLIMOD HYDROCHLORIDE (UNII: G926EC510T) (FINGOLIMOD - UNII:3QN8BYN5QF)
Sun Pharmaceutical Industries, Inc.
ORAL
PRESCRIPTION DRUG
Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. Fingolimod is contraindicated in patients who have: - in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization or Class III/IV heart failure - a history or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker [see Warnings and Precautions (5.1)] - a baseline QTc interval ≥ 500 msec - cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs - had a hypersensitivity reaction to fingolimod or any of the excipients in fingolimod capsules. Observed reactions include rash, urticaria and angioedema upon treatment initiation [see Warni
0.5 mg fingolimod capsules are supplied as follows: Hard gelatin capsule, size '4' yellow cap and white body, axially imprinted with '064' on cap and on body in black ink, filled with white to off-white powder. Bottles of 30 with child resistant cap……………………………………...NDC 62756-064-83 Bottles of 90 with child resistant cap……………………………………...NDC 62756-064-81 Carton of 28 capsules containing 2 blister cards of 14 capsules per blister card NDC 62756-064-96 Carton of 7 capsules containing 1 blister card of 7 capsules per blister card NDC 62756-064-59 Fingolimod capsules should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from moisture.
Abbreviated New Drug Application
Sun Pharmaceutical Industries, Inc. ---------- MEDICATION GUIDE Dispense with Medication Guide available at: https://www.sunpharma.com/usa/products MEDICATION GUIDE Fingolimod (fin-GOL-i-mod) Capsules Read this Medication Guide before you start taking fingolimod capsules and each time you get a refill. There may be new information. If you are the parent of a child who is being treated with fingolimod capsules, the following information applies to your child. This information does not take the place of talking to your doctor about your medical condition or your treatment. What is the most important information I should know about fingolimod capsules? Fingolimod capsules may cause serious side effects, including: 1. Slow heart rate (bradycardia or bradyarrhythmia) when you start taking fingolimod capsules. Fingolimod capsules can cause your heart rate to slow down, especially after you take your first dose. You will have a test, called an electrocardiogram (ECG), to check the electrical activity of your heart before you take your first dose of fingolimod capsules. All adults and children will be observed by a healthcare professional for at least 6 hours after taking their first dose of fingolimod capsules. After you take your first dose of fingolimod capsules: • Your pulse and blood pressure should be checked every hour. • You should be observed by a healthcare professional to see if you have any serious side effects. If your heart rate slows down too much, you may have symptoms, such as: • dizziness • tiredness • feeling like your heart is beating slowly or skipping beats • chest pain • If you have any of the symptoms of slow heart rate, they will usually happen during the first 6 hours after your first dose of fingolimod capsules. Symptoms can happen up to 24 hours after you take your first fingolimod capsules dose. • 6 hours after you take your first dose of fingolimod capsules you will have another ECG. If your ECG shows any heart problems or if your heart rate is still too low or continues to d Les hele dokumentet
FINGOLIMOD - FINGOLIMOD CAPSULE SUN PHARMACEUTICAL INDUSTRIES, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE FINGOLIMOD CAPSULES SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR FINGOLIMOD CAPSULES. FINGOLIMOD CAPSULES, FOR ORAL USE INITIAL U.S. APPROVAL: 2010 RECENT MAJOR CHANGES Warning and Precautions (5.3, 5.9) 8/2023 INDICATIONS AND USAGE (1) Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. (1) (1) (1) DOSAGE AND ADMINISTRATION Assessments are required prior to initiating fingolimod capsules. (2.1) Recommended dosage for adults and pediatric patients (10 years of age and older) weighing more than 40 kg: 0.5 mg orally once-daily, with or without food. (2.2, 2.3) First-Dose Monitoring (including reinitiation after discontinuation greater than 14 days and dose increases): Observe all patients for bradycardia for at least 6 hours; monitor pulse and blood pressure hourly. Electrocardiograms (ECGs) prior to dosing and at end of observation period required. (2.4) Monitor until resolution if heart rate < 45 beats per minute (bpm) in adults, < 55 bpm in patients aged 12 years and above, or < 60 bpm in pediatric patients aged 10 to below 12 years, atrioventricular (AV) block, or if lowest postdose heart rate is at the end of the observation period. (2.4) Monitor symptomatic bradycardia with ECG until resolved. Continue overnight if intervention is required; repeat first-dose monitoring for second dose. (2.4) Observe patients overnight if at higher risk of symptomatic bradycardia, heart block, prolonged QTc interval, or if taking drugs with known risk of torsades de pointes. (2.4, 7.1) DOSAGE FORMS AND STRENGTHS 0.5 mg hard capsules (3) (3) CONTRAINDICATIONS Recent myocardial infarction, unstable angina Les hele dokumentet